In a scientific trial performed in South Africa and Uganda, a twice-yearly injection of lenacapavir has demonstrated whole safety towards HIV an infection amongst younger ladies.
This breakthrough was revealed in the course of the randomised section of the trial, the place not one of the 2,134 ladies who acquired lenacapavir contracted HIV, revealing a 100% efficacy charge.
The first goal of the trial was to guage whether or not a six-month injection of lenacapavir may supply higher safety towards HIV an infection in comparison with two current every day tablet drugs, each of that are pre-exposure prophylaxis (PrEP) medication. The examine targeted on ladies between the ages of 16 and 25, a demographic extremely susceptible to HIV.
Doctor-scientist Linda-Gail Bekker, who led the South African phase of the examine, emphasised the importance of those findings.
She famous that the trial not solely assessed the protection and efficacy of the lenacapavir injection but additionally in contrast it towards Truvada (F/TDF) and Descovy (F/TAF), two every day PrEP capsules.
Truvada has been a cornerstone in HIV prevention for over a decade, extensively used on account of its confirmed effectiveness.
The outcomes counsel a promising future for lenacapavir as a most well-liked PrEP possibility, providing an efficient and handy various to every day capsules.
Associated
